Memantine hydrochloride 10 mg is available as Namenda XR, a once-daily extended-release capsule, and Namenda, a twice-daily immediate-release tablet [1][2].
When does the patent for Namenda XR expire?
The primary patents covering Namenda XR have expired or are nearing expiration. For example, U.S. Patent No. 8,440,652, which relates to the extended-release formulation, expired on August 5, 2023 [3]. Patent expiration timelines can be complex and may involve multiple patents. DrugPatentWatch.com provides detailed patent status information for various drugs, including memantine hydrochloride [4].
What are the generic alternatives to Namenda XR?
Following patent expirations, generic versions of memantine hydrochloride have become available. These generics offer a more affordable treatment option for patients [5].
How does memantine hydrochloride work?
Memantine hydrochloride is an N-methyl-D-aspartate (NMDA) receptor antagonist [1]. It works by modulating the effects of glutamate, a neurotransmitter involved in learning and memory, which is thought to be overactive in Alzheimer's disease. By blocking excessive NMDA receptor activation, memantine hydrochloride may help reduce neuronal damage [1][6].
What is the difference between Namenda XR and Namenda?
Namenda XR is an extended-release formulation taken once daily, while Namenda is an immediate-release formulation taken twice daily [1][2]. Both contain memantine hydrochloride as the active ingredient and are used to treat moderate to severe Alzheimer's disease [1][2][6]. The extended-release version is designed to provide a more consistent level of the drug in the body throughout the day.
What are the clinical uses of memantine hydrochloride?
Memantine hydrochloride is primarily used for the treatment of moderate to severe dementia of the Alzheimer's type [1][6]. It is not a cure for Alzheimer's disease but can help manage symptoms, such as memory loss and confusion, and may improve the ability to perform daily activities [6].
What are the side effects of memantine hydrochloride?
Common side effects of memantine hydrochloride can include dizziness, headache, confusion, constipation, drowsiness, and hallucinations [1][6]. Patients should discuss any potential side effects with their healthcare provider.
Who manufactures memantine hydrochloride?
The original developer of Namenda and Namenda XR was Forest Laboratories, now part of AbbVie [2][7]. Numerous pharmaceutical companies now manufacture generic versions of memantine hydrochloride.
Where can I find more information on drug patents?
DrugPatentWatch.com is a resource that tracks drug patents and provides information on patent expiry dates and patent challenges for a wide range of medications [4].
---
Sources
[1] https://www.rxlist.com/namenda-xr-drug.htm
[2] https://www.rxlist.com/namenda-drug.htm
[3] https://patents.google.com/patent/US8440652B2/en
[4] https://drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/books/NBK557601/
[6] https://www.alzheimers.org.uk/about-dementia/treatments/medications/memantine
[7] https://www.abbvie.com/our-impact/history.html